MA28531B1 - Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 - Google Patents

Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Info

Publication number
MA28531B1
MA28531B1 MA29385A MA29385A MA28531B1 MA 28531 B1 MA28531 B1 MA 28531B1 MA 29385 A MA29385 A MA 29385A MA 29385 A MA29385 A MA 29385A MA 28531 B1 MA28531 B1 MA 28531B1
Authority
MA
Morocco
Prior art keywords
pdea4
pyrazolo
pyridine
inhibitor
composition
Prior art date
Application number
MA29385A
Other languages
English (en)
French (fr)
Inventor
Siegfried Benjamin Christensen Iv
Caroline Mary Cook
Christopher David Edlin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Amyn Pyarali Sayani
Naimisha Trivedi
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28531B1 publication Critical patent/MA28531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA29385A 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 MA28531B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
MA28531B1 true MA28531B1 (fr) 2007-04-03

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29385A MA28531B1 (fr) 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Country Status (15)

Country Link
US (2) US20080275078A1 (https=)
EP (2) EP1735314A1 (https=)
JP (2) JP2007529464A (https=)
KR (1) KR20060130744A (https=)
AR (1) AR048175A1 (https=)
AU (1) AU2005223351A1 (https=)
BR (1) BRPI0508843A (https=)
CA (1) CA2559629A1 (https=)
IL (1) IL178011A0 (https=)
MA (1) MA28531B1 (https=)
NO (1) NO20064450L (https=)
PE (1) PE20060078A1 (https=)
RU (1) RU2378274C2 (https=)
TW (1) TW200602051A (https=)
WO (2) WO2005090352A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080275078A1 (en) 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
WO2009100169A1 (en) * 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
UY31636A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2419087B1 (en) * 2009-04-13 2013-01-23 Sulur, Vanangamudi Subramaniam A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
ES2610755T3 (es) 2012-08-27 2017-05-03 Aktiebolaget Electrolux Sistema de posicionamiento de un robot
EP2986192B1 (en) 2013-04-15 2021-03-31 Aktiebolaget Electrolux Robotic vacuum cleaner
CN105101855A (zh) 2013-04-15 2015-11-25 伊莱克斯公司 具有伸出的侧刷的机器人真空吸尘器
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015090402A1 (en) 2013-12-19 2015-06-25 Aktiebolaget Electrolux Robotic cleaning device with perimeter recording function
EP3084539B1 (en) 2013-12-19 2019-02-20 Aktiebolaget Electrolux Prioritizing cleaning areas
JP6638987B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス 回転側面ブラシの適応速度制御
EP3082537B1 (en) 2013-12-19 2020-11-18 Aktiebolaget Electrolux Robotic cleaning device and method for landmark recognition
CN105792721B (zh) 2013-12-19 2020-07-21 伊莱克斯公司 以螺旋样式移动的带侧刷的机器人真空吸尘器
CN105849660B (zh) 2013-12-19 2020-05-08 伊莱克斯公司 机器人清扫装置
KR102099495B1 (ko) 2013-12-19 2020-04-09 에이비 엘렉트로룩스 로봇 청소 장치가 장애물에 올라가는 것의 감지
KR102116595B1 (ko) 2013-12-20 2020-06-05 에이비 엘렉트로룩스 먼지통
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016005012A1 (en) 2014-07-10 2016-01-14 Aktiebolaget Electrolux Method for detecting a measurement error in a robotic cleaning device
JP6443897B2 (ja) 2014-09-08 2018-12-26 アクチエボラゲット エレクトロルックス ロボット真空掃除機
EP3190938A1 (en) 2014-09-08 2017-07-19 Aktiebolaget Electrolux Robotic vacuum cleaner
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
EP3230814B1 (en) 2014-12-10 2021-02-17 Aktiebolaget Electrolux Using laser sensor for floor type detection
CN107072454A (zh) 2014-12-12 2017-08-18 伊莱克斯公司 侧刷和机器人吸尘器
JP6532530B2 (ja) 2014-12-16 2019-06-19 アクチエボラゲット エレクトロルックス ロボット掃除機の掃除方法
KR102339531B1 (ko) 2014-12-16 2021-12-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 경험-기반의 로드맵
US11099554B2 (en) 2015-04-17 2021-08-24 Aktiebolaget Electrolux Robotic cleaning device and a method of controlling the robotic cleaning device
WO2017036532A1 (en) 2015-09-03 2017-03-09 Aktiebolaget Electrolux System of robotic cleaning devices
RU2724345C2 (ru) * 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108603935A (zh) 2016-03-15 2018-09-28 伊莱克斯公司 机器人清洁设备以及机器人清洁设备进行陡壁检测的方法
CN109068908B (zh) 2016-05-11 2021-05-11 伊莱克斯公司 机器人清洁设备
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7243967B2 (ja) 2017-06-02 2023-03-22 アクチエボラゲット エレクトロルックス ロボット清掃デバイスの前方の表面のレベル差を検出する方法
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP6989210B2 (ja) 2017-09-26 2022-01-05 アクチエボラゲット エレクトロルックス ロボット清掃デバイスの移動の制御
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
RU2134498C1 (ru) * 1998-12-08 1999-08-10 Таран Александр Иванович Контактный узел
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
CN100439370C (zh) 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2006503108A (ja) * 2002-09-16 2006-01-26 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
AU2004299277A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
US20080275078A1 (en) * 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors

Also Published As

Publication number Publication date
TW200602051A (en) 2006-01-16
US20070280971A1 (en) 2007-12-06
WO2005090354A1 (en) 2005-09-29
KR20060130744A (ko) 2006-12-19
JP2007529464A (ja) 2007-10-25
RU2378274C2 (ru) 2010-01-10
EP1740590A1 (en) 2007-01-10
RU2006132684A (ru) 2008-04-27
AR048175A1 (es) 2006-04-05
JP2007529486A (ja) 2007-10-25
EP1735314A1 (en) 2006-12-27
NO20064450L (no) 2006-11-14
PE20060078A1 (es) 2006-03-10
WO2005090352A1 (en) 2005-09-29
US20080275078A1 (en) 2008-11-06
IL178011A0 (en) 2006-12-31
US7709497B2 (en) 2010-05-04
CA2559629A1 (en) 2005-09-29
BRPI0508843A (pt) 2007-08-28
AU2005223351A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
MA28531B1 (fr) Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
EP1534786A4 (en) COLORING COMPOSITIONS
HRP20150474T1 (xx) PIRIDINOM I KINOLINOM SUPSTITUIRANI PIROLO[1,2-b]PIRAZOL MONOHIDRAT KAO INHIBITOR TGF-BETA
EP1828181A4 (en) PYRROLO [2,3-B] PYRIDINE-4-YL-AMINE AND PYRROLO [2M3-B] PYRIMIDIN-4-YL-AMINE AS JANUSKINASEINHIBITORS
ZA200508300B (en) RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith
SG103904A1 (en) Colored absorbent article
EP1732906A4 (en) 2-AMINOTHIAZONE COMPOUNDS SUITABLE AS ASPARTYL PROTEASE INHIBITORS
NO20071364L (no) 6H-[l] benzopyrano[4,3-b]-kinoliner og deres anvendelse som østrogenmidler
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
IL179149A0 (en) Therapeutic compounds: pyridine as scaffold
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ATE382261T1 (de) Flüssige formulierung
EP1951231A4 (en) CAMPTOTHECIN DERIVATIVES AS CHEMOROSO-SENSITIVE AGENTS
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
AU2003268075A1 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
EP1714656A4 (en) ED-71 preparation
EP1409507A4 (en) COMPOSITIONS, METHODS AND KITS RELATING TO REMODELIN
FR2857363B1 (fr) 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
DE60311273D1 (de) Gemischtes schmuckset
EP1786433A4 (en) BETULINOL DERIVATIVES AS ANTI-HIV MEDIUM
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
AU2002229859A1 (en) Chemical derivatives and their use as anti-telomerase agent
DE60140529D1 (de) Feuerlöschende Zusammensetzung